Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 40 to 90 Women only

Comparing solifenacin or mirabegron with local estrogen to combined pharmacotherapy for overactive bladder

Official title: Efficacy and Safety of Solifenacin or Mirabegron With Local Estrogen Versus Combination Treatment With Mirabegron and Solifenacin for Refractory Overactive Bladder

Run by Mackay Memorial Hospital · NCT06479720 · Data updated 2026-11-12

This study is testing whether combining solifenacin or mirabegron with local estrogen works better than just using solifenacin and mirabegron alone for women with overactive bladder who haven't found relief from other treatments.

More Overactive Bladder trials

Quick facts

PhasePhase 4
Study typeInterventional
Ages40 Years to 90 Years
SexWomen only
Enrollment300 (estimated)
SponsorMackay Memorial Hospital
Academic / other
Locations1 site (Taipei)
StatusRecruiting
StartedJune 16, 2022
Main results expectedJune 30, 2026
Study endsDecember 31, 2026
Registry record updatedMay 9, 2025
Trial IDNCT06479720 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are women with detrusor overactivity who have not found relief from anti-muscarinic medications or mirabegron.

Probably not a fit

Patients with contraindications to solifenacin, mirabegron, or estrogen, as well as those with postvoid urine retention, may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effectiveness of solifenacin or mirabegron combined with local estrogen compared to a combination of solifenacin and mirabegron in women suffering from overactive bladder. Participants with detrusor overactivity who did not respond to previous treatments are enrolled and divided into three groups for treatment. The study evaluates both subjective symptoms related to incontinence and objective measures such as frequency of urination and urgency. Various validated questionnaires are used to assess the impact on quality of life and urinary symptoms.

Why it matters

Potential benefit: If successful, this study could provide a more effective treatment option for women with overactive bladder who have not responded to standard therapies.

How similar studies have gone: While there have been studies on individual treatments for overactive bladder, this specific combination approach is novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients with detrusor overactivity which defined as a urodynamic observation characterized by involuntary detrusor contractions during the filling phase. Those who were refractory to monotherapy with anti-muscarinics were enrolled for prospective study.

Exclusion Criteria:

* Postvoid urine retention before treatment
* Women who had medical illness and contraindication for using solifenacin and mirabegron, such as narrow-angle glaucoma and hypertension
* Concerns for using estrogen include: Women with history of cerebrovascular disease; thromboembolic disorders; gallbladder disease; known or suspected breast carcinoma; estrogen-dependent neoplasm or undiagnosed abnormal genital bleeding.

Where it's running

  • Mackay Memorial Hospital
    Taipei, Taiwan
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.